Somerset Trust Co Has $571,000 Stake in Pfizer Inc. (NYSE:PFE)

Somerset Trust Co reduced its holdings in Pfizer Inc. (NYSE:PFE) by 43.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,521 shares of the biopharmaceutical company’s stock after selling 16,475 shares during the quarter. Somerset Trust Co’s holdings in Pfizer were worth $571,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PFE. Merit Financial Group LLC raised its stake in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after acquiring an additional 48,397 shares during the last quarter. Walker Asset Management LLC increased its holdings in shares of Pfizer by 4.6% in the fourth quarter. Walker Asset Management LLC now owns 11,598 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 513 shares in the last quarter. Saxon Interests Inc. raised its position in Pfizer by 5.9% in the 4th quarter. Saxon Interests Inc. now owns 9,563 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 535 shares during the last quarter. Avanza Fonder AB acquired a new position in Pfizer during the 4th quarter worth $15,857,000. Finally, Wealthcare Advisory Partners LLC boosted its position in Pfizer by 1.5% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 155,044 shares of the biopharmaceutical company’s stock valued at $4,113,000 after buying an additional 2,324 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

NYSE PFE opened at $26.30 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The business has a 50 day simple moving average of $26.09 and a 200 day simple moving average of $28.00. The stock has a market cap of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) EPS. Analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.